Hepatitis B and HIV Cure Network to help people with HIV and hepatitis B
Official title: Hepatitis B and HIV Cure Consortium (BICC)
Funded at Johns Hopkins University · NIH-11423429 · Data updated 2026-11-12
A multinational effort to study why some people with HIV and chronic hepatitis B may eventually lose hepatitis B surface antigen and achieve a functional cure.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 17, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $170,735 |
| NIH project number | 3U19AI188551-02S1 |
| Project ID | NIH-11423429 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults living with HIV and chronic hepatitis B who can be followed long-term at participating international sites.
✕Less likely to help
People without HIV or chronic hepatitis B, or those unable to commit to long-term follow-up, may not benefit directly.
What this research studies
This project builds a large, international group of people living with HIV and chronic hepatitis B to study how a functional cure could be achieved. It uses advanced technologies and a shared clinical repository to analyze samples from diverse genotypes, with liver biopsies and blood draws to track changes over time. The goal is to identify factors linked to sustained HBsAg loss off treatment and to accelerate progress toward a cure that benefits people in the U.S. and around the world. Participation would involve regular follow-up visits and sample collection over several years at multiple sites. The research emphasizes collaboration, rigorous data sharing, and a patient-centered approach to translating findings into future care.
Why it matters
Potential benefit: If successful, this work could bring us closer to a functional cure for HBV in people with HIV, improving liver health and longevity.
How similar studies have gone: The study builds on existing HBV/HIV research using diverse international cohorts and biorepositories, with potential for new insights beyond prior work.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Thio, Chloe L — Johns Hopkins University
- Study coordinator: Thio, Chloe L
Related research
Other NIH-funded projects on the same topics.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
HBV prevention in community pharmacies: a first step in a low-resource setting
This pilot project tests whether hepatitis B screening and vaccination can be integrated into everyday community pharmacy services to reach more people.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
HBV safety with long-acting HIV therapy for people with HIV
A study to understand how long-acting HIV meds affect hepatitis B in people living with HIV and how to best monitor and protect them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.